Cargando…
Molecular Mechanisms of Tumor Cell Resistance to Chemotherapy Targeted Therapies to Reverse Resistance /
Patients with various cancers are treated with conventional chemotherapeutic drugs and the majority responds well to such therapies. However, there is a subset of patients who does not respond initially and another subset who no longer responds to further treatments. Clearly, in those two subsets of...
| Clasificación: | Libro Electrónico |
|---|---|
| Autor Corporativo: | |
| Otros Autores: | |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
New York, NY :
Springer New York : Imprint: Springer,
2013.
|
| Edición: | 1st ed. 2013. |
| Colección: | Resistance to Targeted Anti-Cancer Therapeutics,
1 |
| Temas: | |
| Acceso en línea: | Texto Completo |
MARC
| LEADER | 00000nam a22000005i 4500 | ||
|---|---|---|---|
| 001 | 978-1-4614-7070-0 | ||
| 003 | DE-He213 | ||
| 005 | 20220112135516.0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 130428s2013 xxu| s |||| 0|eng d | ||
| 020 | |a 9781461470700 |9 978-1-4614-7070-0 | ||
| 024 | 7 | |a 10.1007/978-1-4614-7070-0 |2 doi | |
| 050 | 4 | |a RC261-271 | |
| 072 | 7 | |a MJCL |2 bicssc | |
| 072 | 7 | |a MED062000 |2 bisacsh | |
| 072 | 7 | |a MJCL |2 thema | |
| 082 | 0 | 4 | |a 571.978 |2 23 |
| 082 | 0 | 4 | |a 616.994 |2 23 |
| 245 | 1 | 0 | |a Molecular Mechanisms of Tumor Cell Resistance to Chemotherapy |h [electronic resource] : |b Targeted Therapies to Reverse Resistance / |c edited by Benjamin Bonavida. |
| 250 | |a 1st ed. 2013. | ||
| 264 | 1 | |a New York, NY : |b Springer New York : |b Imprint: Springer, |c 2013. | |
| 300 | |a XIII, 260 p. |b online resource. | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 347 | |a text file |b PDF |2 rda | ||
| 490 | 1 | |a Resistance to Targeted Anti-Cancer Therapeutics, |x 2196-551X ; |v 1 | |
| 505 | 0 | |a Preface -- Multidrug resistance in cancer: a tale of ABC drug transporters -- Multidrug resistance: a role for membrane physics, pH and drug transporters -- Mechanisms and potential therapies for acquired resistance to inhibitors targeting the Raf or MEK kinases in cancer -- Mechanisms of resistance to targeted B-Raf therapies -- Role of β1integrins in the complication and drug resistance against lung cancer: targeting β1integrins to eradicate lung cancer -- Aldo-keto reductases as new therapeutic targets for colon cancer chemoresistance -- Overcoming drug resistance through elevation of ROS in cancer -- Cancer stem cells in resistance to cytotoxic drugs: implications in chemotherapy -- Two birds with a stone: molecular cancer therapy targeting signal transduction and DNA repair pathways -- Collateral sensitivity in drug-resistant tumor cells -- Human cancer resistance to trail-apoptotic pathway-targeted therapies -- The dark side of apoptosis -- Index. | |
| 520 | |a Patients with various cancers are treated with conventional chemotherapeutic drugs and the majority responds well to such therapies. However, there is a subset of patients who does not respond initially and another subset who no longer responds to further treatments. Clearly, in those two subsets of patients, the cancer cells exhibit mechanisms of resistance. One of the main challenges facing us to date is to develop new therapies to treat patients with the resistant tumors. The development of new effective therapies will be dependent on delineating the biochemical, molecular, and genetic mechanisms that regulate tumor cell resistance. Such mechanisms have revealed gene products that directly regulate resistance and are targets for therapy. Of interest, several FDA-approved drugs were able to overcome drug resistance and have been successfully used clinically. They have been used as monotherapy or synergized with other therapies for the treatment of resistant tumors. This volume constitutes a total of twelve selective reviews by pioneer scientists in the field of cancer drug resistance. Specific mechanisms in drug resistance are reviewed and novel approaches are being proposed for therapeutic interventions. This volume is of general interest to scientists, clinicians, health care providers, and students. | ||
| 650 | 0 | |a Cancer. | |
| 650 | 0 | |a Cell death. | |
| 650 | 0 | |a Cytology. | |
| 650 | 0 | |a Medical microbiology. | |
| 650 | 1 | 4 | |a Cancer Biology. |
| 650 | 2 | 4 | |a Cell Death. |
| 650 | 2 | 4 | |a Cell Biology. |
| 650 | 2 | 4 | |a Medical Microbiology. |
| 700 | 1 | |a Bonavida, Benjamin. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 710 | 2 | |a SpringerLink (Online service) | |
| 773 | 0 | |t Springer Nature eBook | |
| 776 | 0 | 8 | |i Printed edition: |z 9781489988416 |
| 776 | 0 | 8 | |i Printed edition: |z 9781461470717 |
| 776 | 0 | 8 | |i Printed edition: |z 9781461470694 |
| 830 | 0 | |a Resistance to Targeted Anti-Cancer Therapeutics, |x 2196-551X ; |v 1 | |
| 856 | 4 | 0 | |u https://doi.uam.elogim.com/10.1007/978-1-4614-7070-0 |z Texto Completo |
| 912 | |a ZDB-2-SBL | ||
| 912 | |a ZDB-2-SXB | ||
| 950 | |a Biomedical and Life Sciences (SpringerNature-11642) | ||
| 950 | |a Biomedical and Life Sciences (R0) (SpringerNature-43708) | ||